Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Norén GN"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Drug Safety; 2013, Vol. 36 Issue 1, p63-70, 8p
Autor:
Star K, Norén GN, Nordin K, Edwards IR, Star, Kristina, Norén, G Niklas, Nordin, Karin, Edwards, I Ralph
Publikováno v:
Drug Safety; 2011, Vol. 34 Issue 5, p415-428, 14p
Publikováno v:
Drug Safety; 2010, Vol. 33 Issue 7, p527-534, 8p
Autor:
Hopstadius J, Norén GN, Bate A, Edwards IR, Hopstadius, Johan, Norén, G Niklas, Bate, Andrew, Edwards, I Ralph
Publikováno v:
Drug Safety; 2008, Vol. 31 Issue 11, p1035-1048, 14p
Autor:
Hopstadius J, Norén GN, Bate A, Edwards IR, Hopstadius, Johan, Norén, G Niklas, Bate, Andrew, Edwards, I Ralph
Publikováno v:
Drug Safety; 2008, Vol. 31 Issue 12, p1145-1147, 3p
Autor:
Fusaroli M; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. michele.fusaroli2@unibo.it., Salvo F; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France. francesco.salvo@u-bordeaux.fr.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France. francesco.salvo@u-bordeaux.fr., Begaud B; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France., AlShammari TM; College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia., Bate A; Global Safety, GSK, Brentford, UK.; Department of Non-Communicable Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Battini V; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Brueckner A; Novartis Pharma AG, Basel, Switzerland., Candore G; Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Carnovale C; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Crisafulli S; Department of Medicine, University of Verona, Verona, Italy., Cutroneo PM; Unit of Clinical Pharmacology, Sicily Pharmacovigilance Regional Centre, University Hospital of Messina, Messina, Italy., Dolladille C; UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University, Caen, France.; Department of Pharmacology, CHU de Caen Normandie, Caen, France., Drici MD; Department of Clinical Pharmacology, Université Côte d'Azur Medical Center, Nice, France., Faillie JL; Desbrest Institute of Epidemiology and Public Health, Department of Medical Pharmacology and Toxicology, INSERM, Univ Montpellier, Regional Pharmacovigilance Centre, CHU Montpellier, Montpellier, France., Goldman A; Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Hauben M; Pfizer Inc, New York, NY, USA.; Department of Family and Community Medicine, New York Medical College, Valhalla, New York, USA., Herdeiro MT; Department of Medical Sciences, IBIMED-Institute of Biomedicine, University of Aveiro, 3810-193, Aveiro, Portugal., Mahaux O; Global Safety, GSK, Brentford, UK., Manlik K; Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Montastruc F; Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France.; CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France., Noguchi Y; Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Noseda R; Institute of Pharmacological Sciences of Southern Switzerland, Division of Clinical Pharmacology and Toxicology, Ente Ospedaliero Cantonale, Lugano, Switzerland., Onakpoya IJ; Department for Continuing Education, University of Oxford, Oxford, UK., Pariente A; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Poluzzi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salem M; Health Canada, Ottawa, ON, Canada., Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden.; Centre for Evidence-Based Medicine, Nuffield, Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Trinh NTH; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway., Tuccori M; Tuscany Regional Centre, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy., van Hunsel F; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.; PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., van Puijenbroek E; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.; PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Khouri C; Pharmacovigilance Department, Université Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France.; UMR 1300-HP2 Laboratory, Université Grenoble Alpes, INSERM, Grenoble Alpes University, Grenoble, France.
Publikováno v:
Drug safety [Drug Saf] 2024 Jun; Vol. 47 (6), pp. 585-599. Date of Electronic Publication: 2024 May 07.
Autor:
Fusaroli M; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salvo F; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Begaud B; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France., AlShammari TM; College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia., Bate A; Global Safety, GSK, Brentford, UK.; Department of Non-Communicable Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Battini V; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Brueckner A; Novartis, Basel, Switzerland., Candore G; Bayer AG, Medical Affairs and Pharmacovigilance, Berlin, Germany., Carnovale C; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Crisafulli S; Department of Medicine, University of Verona, Verona, Italy., Cutroneo PM; Unit of Clinical Pharmacology, Sicily Pharmacovigilance Regional Centre, University Hospital of Messina, Messina, Italy., Dolladille C; UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University, Caen, France.; Department of Pharmacology, CHU de Caen Normandie, Caen, France., Drici MD; Department of Clinical Pharmacology, Université Côte d'Azur Medical Center, Nice, France., Faillie JL; Desbrest Institute of Epidemiology and Public Health, Department of Medical Pharmacology and Toxicology, INSERM, Univ Montpellier, Regional Pharmacovigilance Centre, CHU Montpellier, Montpellier, France., Goldman A; Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Hauben M; Pfizer Inc., New York, USA.; Department of Family and Community Medicine, New York Medical College, Valhalla, New York, USA., Herdeiro MT; Department of Medical Sciences, IBIMED-Institute of Biomedicine, University of Aveiro, 3810-193, Aveiro, Portugal., Mahaux O; Global Safety, GSK, Brentford, UK., Manlik K; Bayer AG, Medical Affairs and Pharmacovigilance, Berlin, Germany., Montastruc F; Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France.; CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France., Noguchi Y; Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Noseda R; Institute of Pharmacological Sciences of Southern Switzerland, Division of Clinical Pharmacology and Toxicology, Ente Ospedaliero Cantonale, Lugano, Switzerland., Onakpoya IJ; Department for Continuing Education, University of Oxford, Oxford, UK., Pariente A; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Poluzzi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salem M; Health Canada, Ottawa, Canada., Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden.; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Trinh NTH; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway., Tuccori M; Tuscany Regional Centre, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy., van Hunsel F; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.; University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, Groningen, the Netherlands., van Puijenbroek E; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.; University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, Groningen, the Netherlands., Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. emanuel.raschi@unibo.it., Khouri C; Pharmacovigilance Department, Univ. Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France. ckhouri@chu-grenoble.fr.; UMR 1300-HP2 Laboratory, Univ. Grenoble Alpes, INSERM, Grenoble Alpes University, Grenoble, France. ckhouri@chu-grenoble.fr.
Publikováno v:
Drug safety [Drug Saf] 2024 Jun; Vol. 47 (6), pp. 575-584. Date of Electronic Publication: 2024 May 07.
Autor:
Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden. daniele.sartori@who-umc.org.; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. daniele.sartori@who-umc.org., Aronson JK; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Erlanson N; Uppsala Monitoring Centre, Uppsala, Sweden., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Onakpoya IJ; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Publikováno v:
Drug safety [Drug Saf] 2024 May; Vol. 47 (5), pp. 475-485. Date of Electronic Publication: 2024 Feb 24.